ELVN Stock Analysis: Buy, Sell, or Hold?
ELVN - Enliven Therapeutics, Inc. Common Stock
$46.74
1.64 (3.64%)
▲
5d:
+1.32%
30d:
+11.66%
90d:
+61.01%
BUY
MODERATE Confidence
Analysis Updated: Jun 22, 2026 12:00 AM ET
Earnings: Aug 12, 2026
Smart Money Distribution
None View Scanner →
Strength: 7.8/10
Get Alerted When ELVN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: ELVN shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: ELVN shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: ELVN is currently trading at $46.74, which is considered extended relative to its 30-day fair value range of $36.77 to $43.82.
Technical Outlook: Technically, ELVN is in a strong uptrend. Immediate support is located at $33.45, while resistance sits at $48.52. The stock is showing strong short-term momentum, up 3.6% recently.
Market Sentiment: ELVN has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $60.11 (+33.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ELVN is in a strong uptrend. Immediate support is located at $33.45, while resistance sits at $48.52. The stock is showing strong short-term momentum, up 3.6% recently.
Market Sentiment: ELVN has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $60.11 (+33.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$36.77 -
$43.82
Company Quality Score
61/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BEARISH: Price extended above range (+6.7% above its trading range)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.6%)
- BULLISH: Trading 33.3% below Wall St target ($60.11)
Trading Range Analysis
30-Day Trading Range
$36.77 -
$43.82
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$33.45
Resistance Level
$48.52
Current Trend
Strong Uptrend
Technical data as of
Jun 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-18.56
Wall Street Target
$60.11
(+33.3%)
Share & Embed Analysis
Last updated: June 22, 2026 2:19 PM ET
Data refreshes hourly during market hours. Next update: 3:19 PM
Data refreshes hourly during market hours. Next update: 3:19 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ELVN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
10
Sells
Net
INSIDERS SELLING
Recent Transactions
Benjamin Hohl
SELL
10000 shares
2026-03-06
Richard A Heyman
SELL
1230 shares
2026-02-17
Joseph P Lyssikatos
SELL
5000 shares
2026-02-06
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 59 HOLD |
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$436 | 55 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$549 | 69 BUY |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$84 | 58 HOLD |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$58 | 52 HOLD |
Advanced ELVN Option Strategies
Professional options setups generated by AI based on today's ELVN price and gamma walls.
